5 research outputs found
Mitosin and DNA topoisomerase II alpha: Two novel proliferation markers in the prognostication of diffuse astrocytoma patient survival
The expression of two novel proliferation-associated markers, mitosin
and topoisomerase II alpha (Topo II alpha), was evaluated
immunohistochemically in consecutive paraffin sections from 60 diffuse
astrocytomas (grades 2 to 4) in relation to clinicopathologic
parameters, proliferating cell nuclear antigen (PCNA) and Ki-67 (MIB-1)
expression and survival. The percentage of mitosin and Topo II alpha
-positive cells (LI) increased with grade and Ki-67 LI, but could not
discriminate between grade 3 on the one hand and grades 2 or 4 on the
other hand. In 51% of cases, Ki-67 LI exceeded Topo II alpha LI,
especially within grade 4. Topo II alpha and mitosin expression was
adversely related to overall and disease-free survival in the entire
cohort and in grades 2/3. However, only Topo II alpha LI affected
disease-free survival in grade 4 tumors. Multivariate analysis selected
only mitosin LI along with the age of the patient, as the independent
parameters predicting overall survival. whereas Topo II alpha emerged as
the single independent predictor of disease-free survival. It is
concluded that the proliferative potential of astrocytomas, as measured
by mitosin and Topo II alpha immunostaining, conveys useful prognostic
information, in addition to that obtained by standard clinicopathologic
parameters
Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients
Purpose: To identify prognostic molecular profiles in patients with mRCC treated with sunitinib, we performed immunohistochemical analysis for VEGF and PI3K/Akt/mTOR pathway components. Methods: The immunohistochemical expression of VEGF, p85α, p110γ, PTEN, p-Akt, p-mTOR, p-4E-BP1 and p-p70S6K was studied in 79 patients with mRCC who received first-line treatment with sunitinib. Expression was correlated with clinicopathological features and survival. Results: VEGF was highly expressed (median H-Score 150), while positivity for the markers of the PI3K/Akt/mTOR pathway was: p85α 43/66 (65 %), p110γ41/60 (68 %), PTEN 32/64 (50 %), p-Akt57/63 (90 %), p-mTOR48/64 (75 %), p-4E-BP1 58/64 (90 %) and p-p70S6K 60/65 (92 %). No single immunohistochemical marker was found to have prognostic significance. Instead, the combination of increased p-mTOR and low VEGF expression was adversely correlated with overall survival (OS) (3.2 vs. 16.9 months, P = 0.001). Conclusion: Immunohistochemistry for VEGF and p-mTOR proteins may discriminate patients refractory to first-line sunitinib with poor prognosis. Prospective validation of our findings is needed. © 2016, Springer-Verlag Berlin Heidelberg
Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients
Purpose: To identify prognostic molecular profiles in patients with mRCC treated with sunitinib, we performed immunohistochemical analysis for VEGF and PI3K/Akt/mTOR pathway components. Methods: The immunohistochemical expression of VEGF, p85α, p110γ, PTEN, p-Akt, p-mTOR, p-4E-BP1 and p-p70S6K was studied in 79 patients with mRCC who received first-line treatment with sunitinib. Expression was correlated with clinicopathological features and survival. Results: VEGF was highly expressed (median H-Score 150), while positivity for the markers of the PI3K/Akt/mTOR pathway was: p85α 43/66 (65 %), p110γ41/60 (68 %), PTEN 32/64 (50 %), p-Akt57/63 (90 %), p-mTOR48/64 (75 %), p-4E-BP1 58/64 (90 %) and p-p70S6K 60/65 (92 %). No single immunohistochemical marker was found to have prognostic significance. Instead, the combination of increased p-mTOR and low VEGF expression was adversely correlated with overall survival (OS) (3.2 vs. 16.9 months, P = 0.001). Conclusion: Immunohistochemistry for VEGF and p-mTOR proteins may discriminate patients refractory to first-line sunitinib with poor prognosis. Prospective validation of our findings is needed. © 2016, Springer-Verlag Berlin Heidelberg